The Emerging Multiple Modality Treatment Based on Systemic Therapy for Hepatocellular Carcinoma (HCC)
As the rapid development of systemic therapy for HCC in past 4 years, multi-modality treatments of systemic therapy combined with such as surgery, TACE, transplantation, as well as related prognostic biomarkers became current hotspots. This subject aims to collect valuable evidence with various perspective to provide reference for questions frequently discussed in clinical practice of HCC treatment. The quickly evolving systemic therapies have improved the HCC patients’ survival dramatically and changed the landscape of whole-course management. With all these systemic therapies emerging, multi-modality treatment such as systemic therapy combined with locoregional therapy, different combinations of systemic treatment compounds with variable mechanisms, are developing quickly, followed by lots of discussion and controversy during this course. While in fact, there’s not much high-level evidence helping us to make appropriate conclusions. Thus, the guest editor-in-chief of this subject, which consists of a team of experts from China as well as Germany, will review the quality and significance of the research from a relevant perspective.
Edited by
Hui-Chuan Sun(Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University)
Ming Kuang(First Affiliated Hospital (FAH), Sun Yat-sen University (SYSU); Zhongshan School of Medicine, SYSU)
Hong zhao(Cancer Hospital Chinese Academy of Medical Sciences)